Expression characteristics and prognostic value of mycoplasma pneumoniae DNA, Interleukin-6, and Interleukin-10 levels in children with mycoplasma pneumoniae pneumonia

Abstract

Objectives: To investigate the expression characteristics and prognostic value of Mycoplasma pneumoniae DNA (MP-DNA), interleukin-6 (IL-6), and interleukin-10 (IL-10) levels in children with Mycoplasma pneumoniae pneumonia (MPP).

Methodology: This was a retrospective analysis of two hundred children who were suspected of having MPP from January 2022 to December 2024 at Yancheng Third People’s Hospital. On the basis of the clinical diagnosis and results of the Mycoplasma pneumoniae culture, the patients were divided into a study group (with MPP, n=103) and a control group (without MPP, n= 97). The study group was divided into a good prognosis group (n=82) and a poor prognosis group (n=21) on the basis of whether they experienced complete resolution of symptoms after treatment, severe complications, or recurrence during the 3-month follow-up. Serum levels of MP-DNA, IL-10, and IL-6 were determined, and their levels in patients with good/poor prognosis were statistically analyzed to explore the risk factors for poor prognosis in patients with MPP.

Results: Compared with those in the control group, levels of MP-DNA (t=29.033; p<0.0001), IL-10 (t=18.233; p<0.0001), and IL-6 (t=28.692; p<0.0001) in the study group were greater (P<0.05). MP-DNA (t=27.174; p<0.0001), IL-10 (t=8.400; p<0.0001), and IL-6 (t=8.981; p<0.0001) levels were higher in the poor prognosis group than in the good prognosis group (P<0.05). High levels of MP-DNA, IL-10, and IL-6 are important risk factors for poor prognosis in children with MPP (P<0.05). Compared with individual diagnosis, combined detection of MP-DNA, IL-10, and IL-6 is more effective.

Conclusion: Children with MPP have elevated levels of MP-DNA, IL-10, and IL-6, and their high expression is a risk factor for poor prognosis.